Guowu Wu

机构：Meizhou City People's Hospital, Key Laboratory of Guangdong Province · ORCID：0000-0001-6449-4861

发表论文 31 篇 · 总被引 485 次 · h-index 7

代表论文

• Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma (2020 · Molecular Therapy — Nucleic Acids · 被引 204)
• Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer (2020 · Pharmacological Research · 被引 82)
• Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR -Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases (2023 · JAMA Network Open · 被引 55)
• Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study (2023 · Journal of Thoracic Oncology · 被引 55)
• Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial (2024 · Signal Transduction and Targeted Therapy · 被引 36)
• A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001) (2025 · Journal of Hematology & Oncology · 被引 9)